Syntenin-1 is a promoter and prognostic marker of head and neck squamous cell carcinoma invasion and metastasis

Cui, Li; Cheng, Siliangyu; Liu, Xiaojun; Messadi, Diana V.; Yang, Yan; Hu, Shen

doi:10.18632/oncotarget.13020

Cited by 17 publications

(16 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Observed from the left part of the diagram, there is more percentage of patients with BRCA, UCEC or SKCM mapped to favorable lncRNA phenotypes compared to patients with HNSC, which represents patients with the first three cancer types tended to have better overall prognosis than patients with HNSC. This result is consistent with the literature [37][38][39], i.e. BRCA, UCEC, and SKCM patients have a much higher five-year survival rate (>90%, 90%, and 92% respectively) compared to HNSC (50%).…”

Section: B Mapping Of 5-lncrna Signature To Patient Prognosissupporting

confidence: 93%

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Bao

Wang

et al. 2021

IEEE J. Biomed. Health Inform.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) have emerged as potential prognostic markers in various human cancers as they participate in many malignant behaviors. However, the value of lncRNAs as prognostic markers among diverse human cancers is still under investigation, and a systematic signature based on these transcripts that related to pan-cancer prognosis has yet to be reported. In this study, we proposed a framework to incorporate statistical power, biological rationale, and machine learning models for pan-cancer prognosis analysis. The framework identified a 5-lncRNA signature (ENSG00000206567, PCAT29, ENSG00000257989, LOC388282, and LINC00339) from TCGA training studies (n=1,878). The identified lncRNAs are significantly associated (all P ≤1.48E-11) with overall survival (OS) of the TCGA cohort (n=4,231). The signature stratified the cohort into low-and high-risk groups with significantly distinct survival outcomes (median OS of 9.84 years versus 4.37 years, log-rank P=1.48E-38) and achieved a time-dependent ROC/AUC of 0.66 at 5 years. After routine clinical factors involved, the signature demonstrated better performance for long-term prognostic estimation (AUC of 0.72). Moreover, the signature was further evaluated on two independent external cohorts (TARGET, n=1,122; CPTAC, n=391; National Cancer Institute) which yielded similar prognostic values (AUC of 0.60 and 0.75; logrank P=8.6E-09 and P=2.7E-06). An indexing system was developed to map the 5-lncRNA signature to prognoses of pan-cancer patients. In silico functional analysis indicated that the lncRNAs are associated with common biological processes driving human cancers. The five lncRNAs, especially ENSG00000206567, ENSG00000257989 and LOC388282 that never reported before, may serve as viable molecular targets common among diverse cancers.

show abstract

Section: B Mapping Of 5-lncrna Signature To Patient Prognosissupporting

confidence: 93%

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Bao

Wang

et al. 2021

IEEE J. Biomed. Health Inform.

View full text Add to dashboard Cite

show abstract

“…Currently, surgery, chemotherapy, and radiotherapy remain the major therapeutic strategies for treating HNSCC. Although substantial progress has been achieved in therapy, the prognosis of HNSCC remained little changed in the past few decades (3,4). Currently the TNM staging system is widely used for identifying the HNSCC cases at high risk for unfavorable prognosis.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Robust Immune Prognostic Signature for Head and Neck Squamous Cell Carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is among the most destructive of tumors, leading to considerable morbidity and mortality. Abnormal immune microenvironment is closely associated with tumor progression. This study aimed to construct a robust immune prognostic model for HNSCC. The RNA-seq transcriptome data and clinical information of HNSCC were downloaded from The Cancer Genome Atlas (TCGA) database. The key pathways and transcriptional factors (TFs) that are correlated with significantly altered immune related genes were identified. A robust immune prognostic model was constructed and further validated using a discovery-validation cohort design. An immune prognostic signature-based nomogram model was also developed. We have identified 400 significantly changed immune related genes in HNSCC. In addition, functional analysis of the altered immune related genes revealed many biological functions and pathways that might affect the tumor immune microenvironment. FOXP3, SNAI2, and STAT1 were identified as the hub TFs for regulating immunological changes in HNSCC. Moreover, an immune related gene-based prognostic signature significantly associated with the overall survival (OS) of HNSCC was constructed in the discovery cohort, and successfully validated in the validation cohort. Finally, a nomogram model based on immune prognostic signature was built and exhibited good performance for predicting the OS of HNSCC. In conclusion, the immune prognostic model is robust for predicting the prognosis of HNSCC and may evolve as a promising tool for risk evaluation and therapeutic selection.

show abstract

“…Syntenin-1 can associate with endosome compartments, including Rab5 early endosomes, Rab7 late endosomes, and Rab11 recycling endosomes [3], and these compartments are altered in prostate cancer though changes in endosome gene expression and endosome distribution [4,5,6]. Understanding the roles that syntenin-1 plays in endosome biology is important to determine how this protein supports cancer cell growth and migration [7] and its role in promoting invasion and metastasis in prostate and other cancers [8,9,10]. Syntenin-1 is a specific component of the exosome-biogenesis machinery, which associates with ALIX and syndecan [11], involving interactions on late endosomes.…”

Section: Introductionmentioning

confidence: 99%

A Paradigm in Immunochemistry, Revealed by Monoclonal Antibodies to Spatially Distinct Epitopes on Syntenin-1

Johnson

Sorvina

Logan

et al. 2019

IJMS

View full text Add to dashboard Cite

Syntenin-1 is an essential multi-functional adaptor protein, which has multiple roles in membrane trafficking and exosome biogenesis, as well as scaffolding interactions with either the actin cytoskeleton or focal adhesions. However, how this functional multiplicity relates to syntenin-1 distribution in different endosome compartments or other intracellular locations and its underlying involvement in cancer pathogenesis have yet to be fully defined. To help facilitate the investigation of syntenin-1 biology, we developed two specific monoclonal antibodies (Synt-2C6 and Synt-3A11) to spatially distinct linear sequence epitopes on syntenin-1, which were each designed to be unique at the six-amino acid level. These antibodies produced very different intracellular staining patterns, with Synt-2C6 detecting endosomes and Synt-3A11 producing a fibrillar staining pattern suggesting a cytoskeletal localisation. Treatment of cells with Nocodazole altered the intracellular localisation of Synt-3A11, which was consistent with the syntenin-1 protein interacting with microtubules. In prostate tissue biopsies, Synt-3A11 defined atrophy and early-stage prostate cancer, whereas Synt-2C6 only showed minimal interaction with atrophic tissue. This highlights a critical need for site-specific antibodies and a knowledge of their reactivity to define differential protein distributions, interactions and functions, which may differ between normal and malignant cells.

show abstract

Syntenin-1 is a promoter and prognostic marker of head and neck squamous cell carcinoma invasion and metastasis

Cited by 17 publications

References 24 publications

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Identification of lncRNA Signature Associated With Pan-Cancer Prognosis

Development and Validation of a Robust Immune Prognostic Signature for Head and Neck Squamous Cell Carcinoma

A Paradigm in Immunochemistry, Revealed by Monoclonal Antibodies to Spatially Distinct Epitopes on Syntenin-1

Contact Info

Product

Resources

About